Ravi S Narayan, Ana Gasol, Paul L G Slangen, Fleur M G Cornelissen, Tonny Lagerweij, Hou Y Y E Veldman, Rogier Dik, Jaap van den Berg, Ben J Slotman, Tom Würdinger, Daphne A Haas-Kogan, Lukas J A Stalpers, Brigitta G Baumert, Bart A Westerman, Jan Theys, Peter Sminia
Glioblastoma (GBM) is a highly aggressive and lethal brain cancer type. PI3K and MAPK inhibitors have been studied preclinically in GBM as monotherapy, but not in combination with radiotherapy, which is a key component of the current standard treatment of GBM. In our study, GBM cell lines and patient representative primary cultures were grown as multicellular spheroids. Spheroids were treated with a panel of small-molecule drugs including MK2206, RAD001, BEZ235, MLN0128, and MEK162, alone and in combination with irradiation...
February 2018: Molecular Cancer Therapeutics